The Limited Duration Fund outperformed its benchmark in Q4 2025 with a 1.33 percent return. Review the full performance ...

Why the New Fair Value Target Matters The revised fair value target of US$70.75, up from US$66.88, sits at the center of a wider reset in how analysts are framing the New York Times story, with many ...

Revolution Medicines, Inc. ( RVMD) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 11, 2026 9:30 AM EST ...

Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its ...

WBD says that Netflix is giving it seven days to talk to the David Ellison-led company to try and resolve outstanding concerns and secure a 'best and final' bid, but that it still recommends the ...

GPC announced the pending move alongside reporting 4Q25 and full-year financial results, which showed annual sales at Motion ...

By Nick Zieminski Feb 16 (Reuters) - Run your finger over a map of any American city, and you'll come across many familiar ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

How do you answer Jar Jar paving the way for the rise of the Galactic Empire? You let him start a little rebellion, as a treat.

Written by Ahmed Best and Marc Guggenheim, with art from Kieran McKeown and Laura Braga, colorist Mike Atiyeh, and cover ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...